582/1272 |
ν4
PO43-/Amide III |
Integral |
Mineral-to-matrix ratio (Less susceptible to tissue orientation effects) |
[182] |
960/1272 |
ν1
PO43-/Amide III |
Integral |
Mineral-to-matrix ratio (Strongly sensitive to laser polarization) |
[105] |
1070/960 |
ν1
CO32-/ν1
PO43-
|
Integral |
Mineral
crystallinity (Carbonate-to-phosphate ratio) |
[158] |
1070/1675 |
ν1
CO32-/Amide I |
Integral |
Represents
the labile type-B carbonate content present in the tissue matrix.
(Carbonate-to-matrix ratio) |
[182] |
1375/1272 |
δ(CH2)/Amide III |
Integral |
The relative
amount of proteoglycans |
[231] |
1410/1272 |
β(CH2)/Amide III |
Integral |
The relative
amount of lipids |
[182] |
950/960 |
ACP/ν1 PO43-
|
Integral |
The relative content of immature hydroxyapatite |
[158] |
955/960 |
OCP/ν1 PO43-
|
Integral |
The relative content of immature hydroxyapatite |
[155] |
1070/1103 |
ν1
CO32-/ν1
CO32-
|
Integral |
The relative
content of A, B-type substitution |
[155] |
1209/1181
|
ω(CH2)/ν(C-O-C)
|
Integral
|
Organic Matrix Properties
(Hyp/Pro)
|
[231]
|
1070 |
ν1 CO32-
|
Peak
fitting |
Inversely correlated with the degree of mineral crystallinity
and crystallite length (Full width at half maximum (FWHM)) |
[182] |
960 |
ν1 PO43-
|
Peak
fitting |
Inversely correlated with the degree of mineral crystallinity
and crystallite length (Full width at half maximum (FWHM)) |
[182] |